SNIPR Biome ApS
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Holding
- Established
- 2017-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.sniprbiome.com
Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli PreTransplant
Phase 1
Recruiting
- Conditions
- E Coli InfectionsAllogenic Transplant Patients
- Interventions
- Biological: SNIPR001 consists of genetically modified bacteriophages specifically targeting Escherichia coliOther: Placebo 10 mL
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- SNIPR Biome Aps.
- Target Recruit Count
- 24
- Registration Number
- NCT06938867
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸John Hopkins University, Baltimore, Maryland, United States
A Study Investigating the Safety, Recovery, and Pharmacodynamics of Multiple Oral Administrations of SNIPR001 in Healthy Subjects
Phase 1
Completed
- Conditions
- E.Coli InfectionsBloodstream Infection
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-03-14
- Last Posted Date
- 2023-05-17
- Lead Sponsor
- SNIPR Biome Aps.
- Target Recruit Count
- 36
- Registration Number
- NCT05277350
- Locations
- 🇺🇸
Medpace Clinical Pharmacology, Cincinnati, Ohio, United States
© Copyright 2025. All Rights Reserved by MedPath